Last edition
News about "Takeda "
Takeda Becomes a BaseLaunch Partner
BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.
Takeda | 19/12/2025 | By News Bureau
Innovent Biologics and Takeda Finalise Global Collaboration for Next-Generation IO and ADC Therapies
As part of the agreement, Takeda will pay Innovent an upfront payment of USD1.2 billion, including a USD100 million equity investment at HKD112.56 per share.
Takeda | 05/12/2025 | By Dineshwori
Biopharma Firms See 5.7 Percent Market Cap Drop in Q2 2025: Globaldata
Twenty biopharmaceutical companies have reported a 5.7 percent quarter-on-quarter (QoQ) downturn in their combined market capitalisation from USD 3.9 trillion on 31 March, 2025 to USD 3.7 trillion on 30 June, 2025.
Takeda | 01/09/2025 | By Dineshwori | 135
BridGene Biosciences Signs Deal with Takeda to Discover Small Molecule Drugs
Under the terms of the collaboration, BridGene will use its chemoproteomics platform, IMTAC™, to discover novel small molecule drug candidates against challenging targets in immunology and neurology.
Takeda | 26/02/2025 | By Aishwarya | 354
Halozyme Announces Takeda Gets Approval for HYQVIA with ENHANZE in Japan
HYQVIA® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10 percent and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20), which is Halozyme's ENHANZE drug delivery technology.
Takeda | 31/12/2024 | By Aishwarya | 311
Lupin and Takeda to Commercialize Vonoprazan in India
Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.
Takeda | 19/09/2024 | By Aishwarya | 707
Mankind Pharma Signs License Deal with Takeda to Commercialise Acidity Drug in India
Mankind Pharma has signed a non-exclusive patent licence agreement with Takeda Pharmaceuticals for commercialising acidity drug Vonoprazan in the Indian market.
Takeda | 22/07/2024 | By Aishwarya | 779
Takeda Signs Option Deal with Ascentage Pharma to Get Exclusive Global License for Olverembatinib
Takeda has signed an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor.
Takeda | 15/06/2024 | By Aishwarya | 509
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy